Medsamic (Tranexamic Acid)

Tranexamic acid is an antifibrinolytic agent used to manage bleeding disorders and surgical hemorrhage.

• Surgical bleeding: reduces peri‑operative blood loss and the need for transfusion.
• Traumatic hemorrhage: assists in controlling acute bleeding after injury.
• Menorrhagia: lessens heavy menstrual bleeding when other measures are insufficient.
• Dental procedures in hemophilia: minimizes bleeding risk during extractions and surgeries.

• Tranexamic acid competitively inhibits the activation of plasminogen to plasmin, thereby decreasing fibrinolysis. By blocking plasmin formation, it stabilizes formed fibrin clots and reduces the breakdown of clots at sites of vascular injury, leading to decreased bleeding.

Tranexamic acid is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild gastrointestinal discomfort.
• Vomiting: occasional emesis.
• Diarrhea: loose stools.
• Headache: transient cranial pain.
• Dizziness: mild vertigo.
• Injection site pain: local discomfort after IV administration.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Visual disturbances: blurred vision or retinal changes.
• Hypotension: sudden drop in blood pressure.
• Allergic reactions: rash, urticaria, or anaphylaxis.
• Seizures: rare neurologic events.
• Renal impairment: worsening kidney function in susceptible patients.

Tranexamic acid should be used with careful clinical assessment and monitoring.

• Assess thrombotic risk: evaluate patient history for clotting disorders.
• Monitor renal function: adjust use in patients with impaired kidneys.
• Use cautiously in pregnancy: limited data, weigh benefits against potential risks.
• Observe for hypersensitivity: discontinue if severe allergic reaction occurs.
• Review concomitant anticoagulants: consider interaction potential.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tranexamic acid may interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Combined hormonal contraceptives: increased risk of thrombosis.
• Estrogen therapy: heightened clotting potential.
• Direct oral anticoagulants: may reduce anticoagulant efficacy.

Moderate Interactions (Monitor Closely)

• Antiplatelet agents (e.g., aspirin, clopidogrel): monitor bleeding and clotting balance.
• Heparin or low‑molecular‑weight heparin: adjust dosing and monitor coagulation parameters.
• Certain antifibrinolytics (e.g., aminocaproic acid): avoid overlapping therapy.